The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of tumor location.
 
Sosuke Kato
No Relationships to Disclose
Clinical Controlled Trial on the Efficacy of Adjuvant Chemotherapy for Colon Cancer. Results from Cooperative Project No. 15 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer.
 
Kohei Ogawa
No Relationships to Disclose
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasuyuki Kawamoto
Honoraria - Sawai Pharmaceutical Co; Taiho Pharmaceutical
 
Masataka Yagisawa
No Relationships to Disclose
 
Kazuaki Harada
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Kouichi Furukawa
No Relationships to Disclose
 
Takuya Honda
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Takashi Kato
No Relationships to Disclose
 
Takahide Sasaki
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Sakae Ota
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Akira Ueda
No Relationships to Disclose
 
Akira Fukunaga
No Relationships to Disclose
 
Hikari Nagai
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Chugai Pharma; Daiichi Sankyo; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical